Method of administration and treatment
Provided herein are formulations for topical and/or transdermal administration, and methods of using these formulations for the treatment of proliferative diseases related to cancer such as cancers and related conditions, and solid tumors. Also provided are formulations for topical and/or transdermal administration, and methods of using these formulations for melasma, gout, skin disorders, and other diseases and disorders described herein as well as methods for modulating the pH (e.g. raising) of a tissue or microenvironment proximal to a tumor, modulating pH, or improving the effectiveness of know chemotherapeutic agents, immunotherapy and the like for the prevention, treatment of cancers and related conditions described herein.
1. A method for treating rheumatoid arthritis or reducing a symptom of rheumatoid arthritis, the method comprising steps of:
(1) identifying a subject having rheumatoid arthritis or having a symptom thereof; and
(2) topically administering to the identified subject a transdermal formulation,
wherein the transdermal formulation comprises a penetrant or a penetration enhancer and an amount of one or more buffering agents that is effective in treating rheumatoid arthritis or reducing a symptom thereof, and
wherein the one or more buffering agents are selected from sodium bicarbonate, sodium carbonate, a carbonate salt, a bicarbonate salt, a phosphate buffer, TRIS, and lysine
wherein the amount of the one or more buffering agents that is effective in treating rheumatoid arthritis or reducing a symptom thereof is from about 10% to about 56% w/w relative to the formulation.
2. The method of claim 1 , wherein the transdermal formulation comprises two or more buffering agents.
3. The method of claim 2 , wherein the transdermal formulation comprises three or more buffering agents.
4. The method of claim 2 , wherein, when present, the sodium bicarbonate is at a concentration from about 1% to about 35% w/w of the transdermal formulation, the sodium carbonate is at a concentration from about 1% to about 32% w/w of the transdermal formulation, the carbonate salt is at a concentration of about 10% to about 45% w/w of the transdermal formulation, the bicarbonate salt is at a concentration of about 7% to about 32% w/w of the transdermal formulation, the TRIS is at a concentration of about 6% to about 34% w/w of the transdermal formulation, the lysine is at a concentration of about 29% w/w of the transdermal formulation, and/or the phosphate buffer is at a concentration of about 6% to about 34% w/w of the transdermal formulation, and
wherein the amount of the two or more buffering agents that is effective in treating rheumatoid arthritis or reducing a symptom thereof is from about 10% to about 56% w/w relative to the formulation.
5. The method of claim 3 , wherein, when present, the sodium bicarbonate is at a concentration from about 1% to about 35% w/w of the transdermal formulation, the sodium carbonate is at a concentration from about 1% to about 32% w/w of the transdermal formulation, the carbonate salt is at a concentration of about 10% to about 45% w/w of the transdermal formulation, the bicarbonate salt is at a concentration of about 7% to about 32% w/w of the transdermal formulation, the TRIS is at a concentration of about 6% to about 34% w/w of the transdermal formulation, the lysine is at a concentration of about 29% w/w of the transdermal formulation, and/or the phosphate buffer is at a concentration of about 6% to about 34% w/w of the transdermal formulation, and
wherein the amount of the three or more buffering agents that is effective in treating rheumatoid arthritis or reducing a symptom thereof is from about 10% to about 56% w/w relative to the formulation.
6. The method of claim 1 , wherein, when present, the sodium bicarbonate is at a concentration from about 1% to about 35% w/w of the transdermal formulation, the sodium carbonate is at a concentration from about 1% to about 32% w/w of the transdermal formulation, the carbonate salt is at a concentration of about 10% to about 45% w/w of the transdermal formulation, the bicarbonate salt is at a concentration of about 7% to about 32% w/w of the transdermal formulation, the TRIS is at a concentration of about 6% to about 34% w/w of the transdermal formulation, the lysine is at a concentration of about 29% w/w of the transdermal formulation, and/or the phosphate buffer is at a concentration of about 6% to about 34% w/w of the transdermal formulation, and
wherein the amount of the one or more buffering agents that is effective in treating rheumatoid arthritis or reducing a symptom thereof is from about 10% to about 56% w/w relative to the formulation.
7. The method of claim 1 , wherein when the one or more buffering agents comprises sodium bicarbonate, sodium carbonate, a carbonate salt, and/or a bicarbonate salt, the one or more buffering agents is present in an amount from about 10% to about 45% w/w relative to the formulation.
8. The method of claim 7 , wherein the one or more buffering agents present in an amount from about 10% to about 35% w/w relative to the formulation.
9. The method of claim 1 , wherein the transdermal formulation is formulated as a cream, lotion, or ointment.
10. The method of claim 1 , wherein the formulation further comprises menthol.
11. The method of claim 10 , wherein the menthol is at a concentration from about 0.1% to about 5% w/w of the transdermal formulation.
12. The method of claim 11 , wherein the menthol is at a concentration of about 0.5% w/w of the transdermal formulation.
13. The method of claim 1 , wherein the method further comprises administering another therapeutic agent selected from an analgesic, an anti-inflammatory, a corticosteroid, a nonsteroidal anti-inflammatory drug (NSAID), or a disease modifying anti-rheumatic agent (DMAR agent), or a combination thereof and, wherein the DMAR agent is one or more of azathioprine, cyclosporin, gold, hydroxychloroquine, methotrexate, penicallamine, and sulphasalazine.
14. The method of claim 1 , wherein the penetrant or a penetration enhancer comprising one or more of benzyl alcohol, cetyl alcohol, isododecane, isopropyl palmitate (IPP), isopropyl stearate, menthol, phosphatidyl choline, undecane, and lecithin, wherein the lecithin is selected from an egg lecithin, a soy lecithin, and a synthetic lecithin.
15. The method of claim 1 , wherein the transdermal formulation further comprises a source of fatty acids comprising one or more of an alkanoic acid, caprid acid, diacid, ethyloctadecanoic acid, hexanoic acid, lactic acid, lauric acid, a lecithin, linoelaidic acid, linoleic acid, linolenic acid, neodecanoic acid, oleic acid, palmitic acid, pelargonic acid, propionic acid, stearic acid, and vaccenic acid, wherein the lecithin is selected from an egg lecithin, a soy lecithin, and a synthetic lecithin.
16. The method of claim 1 , wherein the transdermal formulation further comprises a source of fatty acids, and a polar solvent, and one or more of a humectant, an emulsifier, a surfactant, and an emollient; and wherein the formulation is formulated as a cream, lotion, or ointment.
17. The method of claim 16 , wherein the emulsifier comprises one or more of cetyl alcohol, polyglyceryl-4 Laurate (Durosoft®), and a phosphatidylcholine (Phospholipon® 90G).
18. The method of claim 16 , wherein the humectant comprises propylene glycol.
19. The method of claim 16 , wherein the surfactant comprises one or more of a polyoxyethylated castor oil derivative, nonoxynol, octoxynol, phenylsulfonate, a poloxamer (e.g., a Pluronic®), a polyoleates, sodium laurate, sodium lauryl sulfate (sodium dodecyl sulfate), sodium oleate, sorbitan dilaurate, sorbitan dioleate, a sorbitan monolaurate, a sorbitan monooleate; sorbitan trilaurate, sorbitan trioleate, a sorbitan monopalmitate, a sorbitan stearate; a polyethylene glycol, a nonylphenyl ether, p-(1,1,3,3-tetramethylbutyl)-phenyl ether (Triton™ X-100), or a polysorbate (e.g., Tween®).
20. A method for treating rheumatoid arthritis or reducing a symptom of rheumatoid arthritis, the method comprising steps of:
(1) identifying a subject having rheumatoid arthritis or having a symptom thereof; and
(2) topically administering to the identified subject a transdermal formulation
wherein the transdermal formulation comprises a buffering agent in an amount that is effective in treating rheumatoid arthritis or reducing a symptom thereof, and
wherein the buffering agent comprises: sodium bicarbonate, sodium carbonate, a second carbonate salt, a second bicarbonate salt, TRIS, and/or lysine, and, optionally, comprises menthol and
wherein the amount of the buffering agent that is effective in treating rheumatoid arthritis or reducing a symptom thereof is from about 10% to about 56% w/w relative to the formulation; and
(3) administering an analgesic, an anti-inflammatory, a corticosteroid, or a nonsteroidal anti-inflammatory drug (NSAID), or a disease modifying anti-rheumatic agent (DMAR agent) before, contemporaneously with, or after administering the transdermal formulation, wherein the DMAR agent, when administered, is one or more of azathioprine, cyclosporin, gold, hydroxychloroquine, methotrexate, penicallamine, and sulphasalazine.